Furthermore, the analysis showed that patients with del(17p) or TP53 mutations had lower response rates to BTKi therapy, indicating that alternative treatment strategies may need to be considered for these patients. Overall, the results of this analysis suggest that age, disease subtype, and combination therapy with BTKi and chemotherapy should be taken into consideration when selecting treatment options for CLL patients. Additionally, zanubrutinib may be preferred over acalabrutinib for monotherapy in CLL patients.
![/data # iw --debug dev wlan0 connect -w "lucky-5g" auth open key 0:1234567890
Usage: iw [options] dev connect [-w] [] [] [auth open|shared] [key 0:abcde d:1:6162636465] [mfp:req/opt/no]
Join the network with ...](https://linuxcpp.0voice.com/zb_users/upload/2023/05/202305162239148267954.png)
![驱动代码
void kalRxTaskletSchedule(struct GLUE_INFO *pr)
{
static unsigned int num = 0;
tasklet_hi_schedule(&pr->rRxTask[(num++)%NR_CPUS]);
// tasklet_hi_schedule(&pr->rRxTask);
DBGLOG(HAL, ERROR,](https://linuxcpp.0voice.com/zb_users/upload/2023/05/202305162226144313964.png)
